This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 4
  • /
  • Alnylam announces extension of review period for n...
News

Alnylam announces extension of review period for new drug vutrisiran to treat ATTR amyloidosis

Read time: 1 mins
Published:5th Apr 2022

Alnylam announces 3-month extension of review period for new drug application for vutrisiran to treat ATTR amyloidosis.

Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, announced that the FDA has extended the review timeline of the New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labelling facility.

Alnylam recently learned that the original third-party secondary packaging and labelling facility the Company planned to use for the vutrisiran launch was recently inspected and the inspection requires classification for the FDA to take action on the vutrisiran NDA. The inspection observations were not directly related to vutrisiran. In order to minimize delays to approval, Alnylam has identified a new facility to pack and label vutrisiran and submitted an amendment to the NDA for review by the FDA. The updated Prescription Drug User Fee Act (PDUFA) goal date to allow for this review is July 14, 2022. No additional clinical data have been requested by the FDA.

Condition: Transthyretin Amyloidosis (ATTR amyloidosis)
Type: drug

Navigating hATTR amyloidosis

The e-learning module below explains the pathophysiology and path to diagnosis of hereditary ATTR amyloidosis, with a focus on polyneuropathy symptoms. Throughout the module, Dr Isabel Conceição, a consultant in neurology and clinical neurophysiology, provides her expert opinion.

Navigating hATTR amyloidosis

The e-learning module below explains the pathophysiology and path to diagnosis of hereditary ATTR amyloidosis, with a focus on cardiac symptoms. Throughout the module, Dr Pablo García-Pavia, a consultant cardiologist, provides his expert opinion.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights